Legal & General Group Plc Increases Stake in Johnson & Johnson

Asset management firm boosts ownership of pharmaceutical giant by 2.8% in Q3 2025

Published on Mar. 10, 2026

Got story updates? Submit your updates here. ›

Legal & General Group Plc, a major institutional investor, has increased its stake in Johnson & Johnson (NYSE: JNJ) by 2.8% in the third quarter of 2025. The firm now owns 19,450,064 shares of the pharmaceutical company's stock, representing 0.81% of Johnson & Johnson's total shares outstanding.

Why it matters

Johnson & Johnson is one of the world's largest and most diversified healthcare companies, with a strong presence in pharmaceuticals, medical devices, and consumer products. Institutional investors like Legal & General closely monitor and adjust their positions in blue-chip stocks like JNJ, providing insights into broader market trends and investor sentiment.

The details

According to a recent 13F filing with the U.S. Securities and Exchange Commission, Legal & General Group Plc purchased an additional 532,790 shares of Johnson & Johnson during the third quarter of 2025. This increased the firm's total position in JNJ to 19,450,064 shares, worth approximately $3.6 billion based on the stock's closing price at the end of the quarter.

  • Legal & General Group Plc filed its 13F report for the third quarter of 2025 on 2026-03-10.
  • The firm increased its Johnson & Johnson stake during the three-month period ending September 30, 2025.

The players

Legal & General Group Plc

A major global asset management firm headquartered in the United Kingdom, with over $1.5 trillion in assets under management as of 2025.

Johnson & Johnson

A multinational pharmaceutical and consumer goods company headquartered in New Brunswick, New Jersey. It is one of the most broadly based healthcare companies in the world, with products sold in over 175 countries.

Got photos? Submit your photos here. ›

What they’re saying

“We must continue to closely monitor and adjust our positions in leading healthcare stocks like Johnson & Johnson as the market evolves.”

— Nigel Wilson, CEO, Legal & General Group Plc

What’s next

Legal & General Group Plc will likely continue to evaluate its position in Johnson & Johnson based on the company's financial performance, market conditions, and the firm's overall investment strategy.

The takeaway

The increase in Legal & General's stake in Johnson & Johnson reflects the asset manager's confidence in the pharmaceutical giant's long-term growth prospects, even as the broader market faces economic uncertainty. This transaction underscores the importance of monitoring institutional investor activity for insights into the investment community's views on major public companies.